Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5,64 M
EBIT 2016 -0,50 M
Net income 2016 -1,54 M
Debt 2016 -
Yield 2016 -
Sales 2017 6,59 M
EBIT 2017 -0,98 M
Net income 2017 -0,37 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 10,2x
Capi. / Sales2017 8,77x
Capitalization 57,8 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
03/14Earnings Release
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
02/09 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
02/09 INTELGENX TECHNOLOGIES : and Tetra Bio-Pharma Announce the Signing of a Term She..
01/31 INTELGENX TECHNOLOGIES : to Webcast, Live, at VirtualInvestorConferences.com on ..
01/30 LIFE SCIENCES & HEALTHCARE INVESTOR : Nasdaq and OTCQX Companies Present Februa..
01/30 INTELGENX TECHNOLOGIES : Presentation Now Available for On-Demand Viewing
01/19 INTELGENX TECHNOLOGIES : Grants Stock Options
01/19 INTELGENX TECHNOLOGIES : Grants Stock Options
01/04 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
01/04 INTELGENX TECHNOLOGIES : Announces Definitive Agreement with Chemo Group for a G..
2016 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Other Events
More news
Sector news : Generic Pharmaceuticals
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJASTRAZENECA : Trial For Breast Cancer Treatment Shows Positive Results
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 68%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..58
OTSUKA HOLDINGS CO LTD2.26%25 737
SUN PHARMACEUTICAL IND..7.05%24 168
ONO PHARMACEUTICAL CO...-1.68%13 131
ASPEN PHARMACARE HOLDI..1.60%10 094
SHANGHAI FOSUN PHARMAC..8.17%8 745
More Results